Dr. Ghislaine Beilin will lecture on Pollogen’s latest anti-aging innovation- the TriLipo MED procedure – during the upcoming IMCAS congress
TriLipo MED is a technological breakthrough that allows practitioners for the first time to treat 4 layers of skin tissue using 3 advanced technologies, all within a single system. TriLipo MED is the ideal non-invasive solution for a wide variety of aesthetic conditions such as wrinkle reduction, skin tightening, cellulite and fat reduction and more.
(PRWEB) January 22, 2012
Dr. Ghislaine Beilin, a renowned aesthetic physician from Paris and an international expert on radiofrequency, lasers, botulinum toxin, fillers and skin pigmentation, will lecture on the TriLipo MED treatment at the upcoming International Master Course on Aging Skin (IMCAS). The 14th annual IMCAS meeting will be held in Paris, France from January 26 to 29, 2012.
Dr. Beilin’s lecture entitled “Skin micro-resurfacing and tightening using the novel Trilipo Med procedure” will take place on Sunday, January 29th, 2012 at 11:30. The TriLipo MED procedure is a breakthrough in aesthetic medicine since it allows practitioners for the first time to safely and effectively treat all four layers of the skin- the epidermis, dermis, hypodermis and muscle using a single system. By treating all four layers, practitioners can significantly improve and rejuvenate most facial and body areas. The anti-aging results are impressive- a significant reduction in wrinkles, lax skin, scars, cellulite and body circumference.
The TriLipo MED procedure is available using a single system, the Maximus platform, which can deliver three advanced proprietary technologies- TriLipo RF, TriLipo DMA and TriFractional. TriLipo radiofrequency (RF) is used for skin tightening, cellulite reduction and fat reduction. The TriLipo dynamic muscle activation (DMA) is used on the body to clear released fat and on the face to “lift” the SMAS (Superficial Muscular Aponeurotic System). The TriFractional technology enables effective fractional skin resurfacing used on delicate areas such as the face, neck and décolleté. Combined, the technologies complement each other to provide enhanced anti-aging results.
Dr. Beilin stated: “Selecting the right technology to get the best body shaping results can be tricky. I have been working with Pollogen’s systems for many years and I am very pleased with the innovative solutions that they provide. I am particularly pleased with the latest TriLipo MED procedure which enables me to treat simultaneously all skin layers: epidermis, dermis, fat and muscles. This allows me to achieve great immediate and long-lasting results in just a few treatments”.
Mr. Amichai Bar-Nir, Pollogen’s CEO stated: “Pollogen launched the TriLipo MED procedure in October 2011 and physicians from all over the world are repeatedly telling us that this is the procedure they have been waiting for. It has never been easier to treat a wide variety of aesthetic needs using a single system. Results are both immediate and long-lasting and patients love the fast ‘walk in walk out’ treatment.”
Pollogen Ltd. is a global leader in the medical aesthetics market providing innovative, safe and effective solutions for women and men that enhance and expand the practice of medical aesthetic professionals. The company offers products to address a range of skin treatments under the industry’s three premier brands: TriPollar, TriLipo and TriFractional.
Pollogen offers a full line of clinically-proven, non-invasive anti-aging facial and body contouring treatment platforms for circumference reduction, cellulite reduction and skin tightening. The company’s medical aesthetic devices, Maximus, Apollo, and Regen XL offer customers clinically-proven, safe and effective anti-aging lunchtime beauty treatments that deliver immediate and long-lasting results. With a distribution network in over 60 countries, Pollogen is providing innovative solutions to medical professionals globally.
For further information, contact:
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/1/prweb9080470.htm